Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × brolucizumab × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 2 1 Macular Degeneration 1

Interventions

Temozolomide 551 Radiotherapy 353 Bevacizumab 227 Magnetic Resonance Spectroscopy 184 Cyclophosphamide 157 Carboplatin 140 Radiosurgery 137 Etoposide 115 Radiation 108 Irinotecan 105 Vincristine 98 Cisplatin 86 Filgrastim 83 Specimen Handling 79 pembrolizumab 77 Nivolumab 74 Lomustine 73 Topotecan 63 Surgical Procedures, Operative 61 Melphalan 53 sargramostim 51 Carmustine 51 Radiotherapy, Intensity-Modulated 48 Isotretinoin 48 Doxorubicin 48 Granulocyte Colony-Stimulating Factor 46 Peripheral Blood Stem Cell Transplantation 45 Erlotinib Hydrochloride 44 Granulocyte-Macrophage Colony-Stimulating Factor 43 Chemotherapy, Adjuvant 43

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡